MAXCYTE INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 143
- Market Cap
- $454.1M
- Website
- http://www.maxcyte.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
Phase 1
Terminated
- Conditions
- Peritoneal MesotheliomaAdenocarcinoma of the OvaryPrimary Peritoneal CarcinomaFallopian Tube Adenocarcinoma
- Interventions
- Biological: MCY-M11
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- MaxCyte, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03608618
- Locations
- 🇺🇸
National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University at St. Louis, Saint Louis, Missouri, United States
News
No news found